Oncternal Therapeutics, Inc. announced that Damien Bresson as Senior Director, Preclinical and Translation Science.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.21 USD | -4.92% | -8.78% | -23.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.44% | 25.56M | |
+22.63% | 47.02B | |
+49.39% | 41.86B | |
-0.16% | 41.76B | |
-4.27% | 28.8B | |
+12.35% | 26.05B | |
-21.62% | 19.15B | |
+3.97% | 12.55B | |
+29.75% | 12.34B | |
-4.23% | 11.82B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science